18/12/2025
🧬 Dose–Response Curve：Nattokinase 多少 FU 才足以進行纖維蛋白分解？
在心血管營養領域，2,000 FU（Fibrinolytic Units） 被全球普遍視為每日攝取的基準劑量。
在 nattiase®，我們關注的不是「越高越好」，而是如何在法規內，為正確的目標選擇正確的劑量。
基礎劑量：2,000 FU
對多數以長期循環健康維持為目標的族群而言，2,000 FU 是穩定且充分的劑量。
研究顯示（Kim et al., 2008；Kurosawa et al., 2015），2,000 FU 有助於血壓支持，並維持自然抗凝平衡。
在多個市場（如歐洲部分國家），2,000 FU 也符合既有攝取指引，被視為兼顧合規與穩定效果的標準劑量。
目標型應用：4,000 FU 劑量層級
當產品設計聚焦於纖維蛋白原（fibrinogen）或凝血因子管理時，研究顯示存在劑量反應。
Hsia et al. (2009) 指出，4,000 FU 可降低 fibrinogen、Factor VII 與 Factor VIII。
而在 Ren et al. (2022) 的研究中，3,600 FU 雖對血脂有影響，但在斑塊大小的改善上未達統計顯著。
這些差異顯示，研究結果高度受到試驗設計、受試者基線條件，以及 Nattokinase 來源影響，單純以 FU 數值解讀效果，可能產生不同結論。
高劑量研究：10,000+ FU
在特定研究條件下，較高劑量顯示出更明確的作用潛力。
Ren et al. (2022) 顯示，10,800 FU 對動脈斑塊具有顯著影響。
這類數據的意義在於呈現酵素的生物作用潛力，而非作為日常攝取建議。任何高劑量設計，都必須同時考量安全性、當地法規與目標族群需求。
nattiase®：提供劑量設計的彈性
nattiase® 提供 20,000–60,000 FU/g 不同規格的原料，目的在於支援多元產品設計。
高規格原料（如 60,000 FU/g）可在小顆膠囊中實現標準 2,000 FU 劑量；多元規格也能同時支援基礎型與進階型產品，兼顧法規與市場需求。
結語
Nattokinase 的價值，在於能被精準調整，而非單一高劑量。成功的產品設計，必須平衡臨床數據、安全性（Lampe & English, 2016）、區域法規與消費者需求。nattiase® 的角色，是提供原料彈性，讓劑量設計回歸科學與責任。
-
Dose–Response Curve: How Much Nattokinase Is Enough for Fibrin Degradation?
In cardiovascular nutrition, 2,000 FU (Fibrinolytic Units) is globally recognized as the baseline daily intake.
At nattiase®, our focus is not on “higher is always better,” but on selecting the right dose for the right objective—while staying strictly within regulatory frameworks.
The Foundation: 2,000 FU
For most consumers seeking long-term circulatory support, 2,000 FU is a stable and sufficient dosage.
Studies by Kim et al. (2008) and Kurosawa et al. (2015) show that 2,000 FU supports healthy blood pressure and helps maintain natural anticoagulant balance.
In many regions, including parts of Europe, this level aligns well with existing intake guidelines and remains the most practical standard for compliance and steady efficacy.
Targeted Support: The 4,000 FU Tier
When formulations are designed for specific goals such as fibrinogen or coagulation factor management, research indicates a dose-dependent response.
Hsia et al. (2009) demonstrated that 4,000 FU reduced fibrinogen, Factor VII, and Factor VIII.
In contrast, Ren et al. (2022) showed that while 3,600 FU affected lipid parameters, it did not achieve statistically significant plaque reduction.
These differences highlight how outcomes depend heavily on trial design, baseline subject conditions, and the source of nattokinase used. Relying solely on FU values without this context can lead to varying interpretations of efficacy.
High-Dose Research: 10,000+ FU
Under specific study conditions, higher doses have demonstrated clearer biological effects.
Ren et al. (2022) reported that 10,800 FU achieved significant plaque reduction.
Such data illustrate the enzyme’s biological potential rather than serving as a recommendation for routine intake. Any high-dose formulation must carefully consider safety, local regulations, and the needs of the intended population.
The nattiase® Advantage: Formulation Flexibility
nattiase® offers raw material specifications ranging from 20,000 to 60,000 FU/g to support diverse formulation strategies.
High-spec ingredients, such as 60,000 FU/g, enable a standard 2,000 FU dose in smaller, consumer-friendly capsules. This range also supports both foundational and advanced products across different regulatory environments.
Conclusion
The true value of nattokinase lies in precise calibration, not in pursuing the highest possible dose. Successful products balance clinical evidence, safety (Lampe & English, 2016), regional regulations, and consumer intent. nattiase® provides the flexibility that allows potency to be defined scientifically and responsibly.
